SCHEMBL21623697

SCHEMBL21623697

CC(C)c1cn2cc(Br)ncc2n1

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798477 0.85 MCHR1 (0.35) MCHR1
SCHEMBL29020722 0.82
SCHEMBL22991025 0.79 MCHR1 (0.33) MCHR1
SCHEMBL15655042 0.76 HDAC1 (0.32)
SCHEMBL31035602 0.75 APP (0.31) MCHR1
SCHEMBL18506079 0.75 MCHR1 (0.41) MCHR1
SCHEMBL23571466 0.73 IRAK4 (0.33) MCHR1
SCHEMBL12248520 0.73 NOS3 (0.32)
SCHEMBL1500198 0.73 PIK3CG (0.55) MCHR1
SCHEMBL1302277 0.72 PIK3CG (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115322199-B Compounds and their use in the treatment of schistosomiasis 默克专利股份有限公司 2024-12-10 CN disclosed
CN-118684667-A Compounds for the treatment of fasciolopsis 默克专利股份有限公司 2024-09-24 CN disclosed
CN-112512636-B Compounds for the treatment of fasciolopsis 默克专利股份有限公司 2024-06-18 CN disclosed
EP-3823728-A1 COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS Merck Patent GmbH (DE) 2021-05-26 EP disclosed
WO-2020016235-A1 COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS MERCK PATENT GMBH (DE) 2020-01-23 WO disclosed